BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105
233 results:

  • 1. EP300/CREBBP acetyltransferase inhibition limits steroid receptor and foxa1 signaling in prostate cancer cells.
    Huttunen J; Aaltonen N; Helminen L; Rilla K; Paakinaho V
    Cell Mol Life Sci; 2024 Apr; 81(1):160. PubMed ID: 38564048
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinically-observed foxa1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
    Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Staufen1 Represses the foxa1-Regulated Transcriptome by Destabilizing foxa1 mRNA in Colorectal cancer Cells.
    Pasterczyk KR; Li XL; Singh R; Zibitt MS; Hartford CCR; Pongor L; Jenkins LM; Hu Y; Zhao PX; Muys BR; Kumar S; Roper N; Aladjem MI; Pommier Y; Grammatikakis I; Lal A
    Mol Cell Biol; 2024; 44(2):43-56. PubMed ID: 38347726
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Spatial architectures of somatic mutations in normal prostate, benign prostatic hyperplasia and coexisting prostate cancer.
    Chae J; Jung SH; Choi EJ; Kim JW; Kim NY; Moon SW; Lee JY; Chung YJ; Lee SH
    Exp Mol Med; 2024 Feb; 56(1):168-176. PubMed ID: 38172600
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Chromatin accessibility and pioneer factor foxa1 restrict glucocorticoid receptor action in prostate cancer.
    Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
    Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Unveiling the Molecular Landscape of
    Hwang KW; Yun JW; Kim HS
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958805
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent prostate cancer Cells.
    Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
    Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
    Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
    J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in prostate cancer.
    Grillo G; Keshavarzian T; Linder S; Arlidge C; Mout L; Nand A; Teng M; Qamra A; Zhou S; Kron KJ; Murison A; Hawley JR; Fraser M; van der Kwast TH; Raj GV; He HH; Zwart W; Lupien M
    Cancer Discov; 2023 Nov; 13(11):2470-2487. PubMed ID: 37694973
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A Druggable foxa1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung cancer.
    Dorso M; Patel PT; Pankov A; Boyer JA; Soni RK; Del Priore IS; Hayatt O; Kulick A; Hagen CJ; de Stanchina E; Junttila MR; Daemen A; Friedman LS; Hendrickson RC; Chandarlapaty S
    Cancer Res Commun; 2023 Sep; 3(9):1788-1799. PubMed ID: 37691854
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. SETD7 functions as a transcription repressor in prostate cancer via methylating foxa1.
    Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Lysosome-dependent foxa1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
    Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
    Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
    Li X; Wang Y; Deng S; Zhu G; Wang C; Johnson NA; Zhang Z; Tirado CR; Xu Y; Metang LA; Gonzalez J; Mukherji A; Ye J; Yang Y; Peng W; Tang Y; Hofstad M; Xie Z; Yoon H; Chen L; Liu X; Chen S; Zhu H; Strand D; Liang H; Raj G; He HH; Mendell JT; Li B; Wang T; Mu P
    Cancer Cell; 2023 Aug; 41(8):1427-1449.e12. PubMed ID: 37478850
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
    Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
    Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Joint analysis of WES and RNA-Seq identify signature genes related to metastasis in prostate cancer.
    Xiang C; Li Y; Wang W; Tao H; Liang N; Wu S; Yu T; Cui X; Xie Y; Zuo H; Lin C; Xu F
    J Cell Mol Med; 2023 Jul; 27(14):1947-1958. PubMed ID: 37378426
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
    Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
    Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. PROTACs in the Management of prostate cancer.
    Yedla P; Babalghith AO; Andra VV; Syed R
    Molecules; 2023 Apr; 28(9):. PubMed ID: 37175108
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.
    Singh R; Meng H; Shen T; Lumahan LEV; Nguyen S; Shen H; Dasgupta S; Qin L; Karri D; Zhu B; Yang F; Coarfa C; O'Malley BW; Yi P
    Proc Natl Acad Sci U S A; 2023 May; 120(20):e2218229120. PubMed ID: 37155905
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.
    Sattari M; Kohvakka A; Moradi E; Rauhala H; Urhonen H; Isaacs WB; Nykter M; Murtola TJ; Tammela TLJ; Latonen L; Bova GS; Kesseli J; Visakorpi T
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140987
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.